- Case-Based Roundtable
- General Dermatology
- Eczema
- Chronic Hand Eczema
- Chronic Spontaneous Urticaria
- Alopecia
- Aesthetics
- Vitiligo
- COVID-19
- Actinic Keratosis
- Precision Medicine and Biologics
- Rare Disease
- Wound Care
- Rosacea
- Psoriasis
- Psoriatic Arthritis
- Atopic Dermatitis
- Melasma
- NP and PA
- Skin Cancer
- Hidradenitis Suppurativa
- Drug Watch
- Pigmentary Disorders
- Acne
- Pediatric Dermatology
- Practice Management
- Prurigo Nodularis
- Buy-and-Bill
Article
FDA panel backs ustekinumab for treating psoriasis
Silver Springs, Md. - An Food and Drug Administration (FDA) panel ruled Johnson & Johnson's experimental drug, ustekinumab, should be approved for treating moderate to severe psoriasis in adults, Reuters reports.
Silver Springs, Md.
- An Food and Drug Administration (FDA) panel ruled Johnson & Johnson's experimental drug, ustekinumab, should be approved for treating moderate to severe psoriasis in adults, Reuters reports.
Panel members unanimously agreed that the drug's potential to relieve symptoms of psoriasis outweighed concerns that long-term use could increase the risk of cancer.
The FDA will consider advice from the panel before making a final decision in September.
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
